




NaDeNo



NANOSCIENCE AS

A 2022 SINTEF spin-off

UNLEASHING THE POTENTIAL OF HARD TO DELIVER DRUGS



NaDeNo based on decades of research




NaDeNo's proprietary nanoparticle platform

The concept

Hydrophobic drugs **encapsulated** in polymeric nanoparticles, injected into the body by various administration routes.

No chemical modification of drug.

Nanoparticles **degrade** in the body drug is **released** over time.



The impact

- ✓ Protection of drug and patient
- ✓ Increased efficacy
- ✓ Novel delivery opportunities for new and existing hard-to-deliver drugs
- ✓ Possibilities for prolonged drug patent protection




PACAB-002 for treatment of cancer with high unmet need


- Encapsulated anti-cancer **cabazitaxel** for local delivery

- Proven**


- ✓ Long drug retention time
- ✓ Tumor-specific drug accumulation
- ✓ Reduced side effects
- ✓ Even intraperitoneal distribution
- ✓ Significant effect in mouse models



1 hr after injection of fluorescently-labelled nanoparticles




Peritoneal metastasis originating from ovarian cancer. Tumor weight at study end (day 38), N=6 mice in each group * $P<.001$



100-150 nm


Our nanotechnology can make a difference

'The majority of these patients will die of their disease' KOL –US




Lead candidate for peritoneal metastasis **600 mUSD**


Ovarian cancer stage III



Colorectal cancer




Gastric



■ No of patients annually ■ PC as sole site of metastasis

64 000 patients

5% licensing fee is substantial even at small penetration rates



NaDeNo has several programs in motion


RoA	API	Indication	Discovery	Proof of concept	Preclinical	Clinical Phase I/II
<u>Proprietary therapeutic programs - oncology</u>						
Local (i.p)	Cabazitaxel	Peritoneal metastasis		PACAB-002		Target 2025
Undisclosed	Undisclosed	Undisclosed		Nondilutive funding		Target 2025
<u>Proprietary drug delivery platform – new proprietary combinations - available for licensing</u>						
Based on POC						

The blue arrows indicate today's status

Together we can do more!



**Partners
for pipeline and
platform
development**



**Seed II
Q4 2023
5 m USD**

Technology for hard to deliver drugs

Contact:

CEO: annbjorg.falck@nadeno.com

Scientific Advisor: ruth.b.schmid@sintef.no

